Generated by AI
Alaunos Therapeutics Inc. is a biopharmaceutical company focused on developing therapies for cancer and metabolic disease. Its current portfolio includes clinical-stage and preclinical programs centered on engineered T-cell receptor approaches for solid tumors, along with oral small-molecule candidates for obesity and related metabolic disorders. The company’s oncology work is aimed at addressing difficult-to-treat cancers through immune-based technologies such as TCR-T cell therapies and proprietary discovery platforms for identifying tumor-specific targets. In metabolic health, Alaunos Therapeutics Inc. is developing non-incretin oral compounds designed to offer an alternative therapeutic approach for obesity and associated conditions. Headquartered in Fort Lauderdale, Florida, and founded in 2003, Alaunos Therapeutics Inc. operates in the biotechnology sector and primarily supports its business through research and development activities.
Website501 E. Las Olas Blvd.
Fort Lauderdale, FL, 33301
United States
The latest articles about TCRT.
Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics (NASDAQ:TCRT)
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. Circle8 Group (NASDAQ:CIRC) stock moved
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 13's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about TCRT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.